L-arginine as a novel target for clinical intervention in inflammatory bowel disease
Arginase-1 (Arg1) and the inducible nitric oxide synthase 2 (NOS2) compete for the common substrate L-arginine, semi-essential amino acid, and central intestinal metabolite. Both enzymes exhibit various, sometimes opposing effects on immune responses, tissue regeneration, or microbial growth and rep...
Guardado en:
Autores principales: | Björn Nüse, Jochen Mattner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Open Exploration Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/795628a54bfe46eca020af5f2c59efd8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Extracellular vesicles derived from gut microbiota in inflammatory bowel disease and colorectal cancer
por: Giusi Alberti, et al.
Publicado: (2021) -
Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center
por: Gianluca Ianiro, et al.
Publicado: (2021) -
Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms
por: Xiufang Cui, et al.
Publicado: (2021) -
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
por: Youlian Zhou, et al.
Publicado: (2018) -
Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
por: Igor G. Bakulin, et al.
Publicado: (2021)